GenSight Biologics (the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharmaceutical company focused on developing and commercializing innovative gene therapies for retinal ...

Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (Nasdaq: APLS). Apellis, a leader in advancing treatments for serious, ...

LUGANO topline data on track for mid-2026, with LUCIA readout to follow shortly after – – Continued favorable safety profile observed in masked ...

Harrow’s analyst narrative has shifted again, with the central fair value price target trimmed from US$70.63 to US$68.38. Behind that adjustment, recent research balances bullish views that still ...

Key market opportunities for Lucentis include its broad approval for multiple retinal diseases, its proven clinical efficacy, and strong physician trust. Despite competition, its established global ...

A new study published in the American Journal of Ophthalmology revealed that retinopathy of prematurity (ROP) is associated ...

Completed Formal Dispute Resolution Meeting with FDA regarding Complete Response Letter (CRL) for ONS-5010; Decision Expected This Month ...

4D Molecular Therapeutics (NASDAQ:FDMT) executives said the company is seeing strong clinical trial momentum for its lead retinal gene therapy candidate, 4D-150, as it advances through late-stage ...

Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (Nasdaq: APLS). Apellis, a ...

PTI Secretary General Salman Akram Raja on Wednesday alleged that PTI founder Imran Khan had lost vision in one eye due to alleged torture during imprisonment and was facing serious health concerns ...

A new study published in the Journal of the American Medical Association found that administration of anti–vascular ...

Imran and Bushra Bibi remain incarcerated in Rawalpindi's Adiala Jail. They were sentenced on December 20, 2025, to 17 years ...